AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois. The company went IPO on 2013-01-02. The company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Mr. Robert Michael es el Chairman of the Board de AbbVie Inc, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción ABBV?
El precio actual de ABBV es de $205.75, ha aumentado un 0.4% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de AbbVie Inc?
AbbVie Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de AbbVie Inc?
La capitalización bursátil actual de AbbVie Inc es $363.6B
¿Es AbbVie Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 31 analistas han realizado calificaciones de análisis para AbbVie Inc, incluyendo 9 fuerte compra, 17 compra, 11 mantener, 0 venta, y 9 fuerte venta